Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule ...

Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...

Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate ...

Stress is known to decrease fertility and sexual behavior, but researchers thought this was because stress hormones lower levels of a brain hormone called gonadotropin releasing hormone, or GnRH.

The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...

Mechanism of action. The efficacy of a GnRH agonist in the treatment of PMS depends on its ability to cause pituitary desensitization to GnRH. Depending on the potency of the agonist, the ...

Please provide your email address to receive an email when new articles are posted on . “Many transgender boys do not want to compromise their adult height,” Sabine E. Hannema, MD, PhD, a pediatric ...